| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000002637 |
| Receipt No. | R000003214 |
| Official scientific title of the study | A randomized, double blind, comparative study of vitamin D3 versus placebo in patients with epithelial ovarian cancer to prevent relapse after operation and chemotherapy |
| Date of disclosure of the study information | 2009/11/01 |
| Last modified on | 2016/04/10 (Ver. 4) |
| Basic information | ||
| Official scientific title of the study | A randomized, double blind, comparative study of vitamin D3 versus placebo in patients with epithelial ovarian cancer to prevent relapse after operation and chemotherapy | |
| Title of the study (Brief title) | Amateras VII | |
| Region |
|
|
| Condition | ||
| Condition | ovarian cancer | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | YES | |
| Objectives | |
| Narrative objectives1 | We will determine if vitamin D3 peroral administration of 2000IU/day for 1 year can prevent death and relapse of ovarian cancer after operation with or without chemotherapy, by conducting a double blind randomized controlled clinical trial. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | total death |
| Key secondary outcomes | relapse |
| In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | YES |
| Dynamic allocation | NO |
| Institution consideration | Institution is not considered as adjustment factor. |
| Blocking | YES |
| Concealment | Central registration |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | vitamin D3 | |
| Interventions/Control_2 | placebo | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required. |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Female | |||
| Key inclusion criteria | 1. First operation with or without chemotherapy for ovarian cancer at Jikei University hospitals and no residual tumor is observed.
2. Obtained informed consent 3. Age 20 and more and less than 80 years old |
|||
| Key exclusion criteria | 1. Already taking vitamin D supplement or 1,25 vitamin D
2. History of kidney stone 3. Other difficulties judged by the surgeon in charge |
|||
| Target sample size | 250 | |||
| Research contact person | |
| Name of lead principal investigator | Mitsuyoshi Urashima |
| Organization | Jikei University School of Medicine |
| Division name | division of molecular epidemiology |
| Address | 3-25-8 Minato-ku, Tokyo |
| TEL | |
| Public contact | |
| Name of contact person | |
| Organization | Jikei University School of Medicine |
| Division name | division of molecular epidemiology |
| Address | |
| TEL | |
| Homepage URL | |
| urashima@jikei.ac.jp | |
| Sponsor | |
| Institute | Jikei University School of Medicine |
| Institute | |
| Department | |
| Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one. |
| Funding Source | |
| Organization | Jikei University School of Medicine |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-bin/icdr_e/ctr_view.cgi?recptno=R000003214 |